Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay.
Yoshiaki NakamuraYuichiro TsukadaNobuhisa MatsuhashiTatsuro MuranoManabu ShiozawaYusuke TakahashiEiji OkiMasahiro GotoYoshinori KagawaAkiyoshi KanazawaTakashi OhtaAkira OuchiHideaki BandoHiroshi UchigataChiemi NotakeHiroaki IkematsuTakayuki YoshinoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Our data demonstrate the potential clinical utility of ctDNA as a tool to improve management of stage II and higher CRC with a methodology that is non-invasive, accessible, and allows for rapid evaluation to inform clinical decisions.